I
Injectsense
Measuring and monitoring therapy effectiveness through miniaturized, autonomous in-vivo sensing and data control
About Injectsense
Injectsense operates at the intersection of advanced semiconductor technology and medical systems, specializing in the development of implantable sensors for continuous medical monitoring. The company's core product is a high-value, miniaturized device that provides reliable, precise, and continuous data transmission to help physicians determine the best course of treatment. Injectsense serves healthcare providers and medical institutions, focusing on improving disease outcomes through evidence-supported therapies. The company partners with major strategic players in the medical field to enhance its technology and expand its market reach. Injectsense's business model revolves around the sale and support of its implantable devices, generating revenue through direct sales and strategic partnerships. The company operates primarily in the medical technology market and aims to change the standard of care with its innovative solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Emeryville, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 70.3/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Risk Management, Hard Tech, DT and LS, science-based
- Technology
- Big Data, Deep Tech, Autonomous & Sensor Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Nov 2023 | $2.5M | $49M | Undisclosed | ↗ |
| GRANT✓Other financing | Mar 2022 | $1.7M | — | National Eye Institute | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Injectsense is 1.8K monthly website visits, up 164.7% over the last three months. Injectsense's team declined 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Eye Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Injectsense on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Injectsense’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.